Drug Trial Radar · NCT06476509
A Study to Assess Serotonin Transporter Occupancy of Healthy Adults Using 11C-DASB PET
Last checked: Nov 19, 2026Latest source record: Jun 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
May 30, 2024
Primary completion
Jan 19, 2025
Study completion May 23, 2025
Sponsor
- Lead sponsor
- Vigonvita Life SciencesIndustry
- Sponsor type
- Industry
- First posted
- Jun 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study was a non-randomized, open-label clinical study to assess Serotonin transporter occupancy in the brain of healthy adults using 11C-DASB positron emission tomography (PET)
Conditions
- Major Depressive Disorder
Interventions
LV232 40mgDrug
oral
Escitalopram 20 mgDrug
oral
LV232 60mgDrug
oral
LV232 20mgDrug
oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Serotonin Transporters occupancyTime frame: baseline and 3 hours after administration on Day 1
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Mental Health Center Ethics Committee
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.